导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.37% | 4166/4766 |
| 近一周 | -4.04% | 4957/5456 |
| 近一月 | -3.35% | 2409/5412 |
| 近一季 | 1.89% | 654/5222 |
| 近半年 | -16.13% | 4143/4911 |
| 近一年 | -23.91% | 4058/4391 |
| 近两年 | -2.05% | 2902/2953 |
| 近三年 | -28.33% | 2194/2252 |
| 成立以来 | -0.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.72% 3925/4961 |
-16.33% 4727/5312 |
- - |
- - |
| 2025 | -2.65% 3339/4813 |
-0.47% 2262/3635 |
-2.13% 3316/4076 |
6.10% 3550/4524 |
-5.81% 3626/4813 |
| 2024 | -4.98% 2254/3463 |
0.92% 924/2808 |
-9.18% 2328/3014 |
13.66% 2139/3129 |
-8.79% 2881/3463 |
| 2023 | -15.71% 1656/2656 |
2.41% 1357/2280 |
-12.05% 2171/2385 |
-0.82% 451/2515 |
-5.65% 1440/2655 |
| 2022 | -11.81% 258/2207 |
-15.79% 1072/1919 |
14.42% 198/2016 |
-8.74% 221/2113 |
0.30% 1513/2208 |
| 2021 | -4.42% 950/1822 |
-5.57% 937/1255 |
4.07% 927/1330 |
-9.29% 1173/1466 |
7.24% 189/1822 |
| 2020 | - - |
- - |
- - |
15.16% 233/1164 |
20.36% 62/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实中证主要消费ETF发起联接A VS. 长安沪深300非周期A(740101) |